While very little data exists investigating the use of immune checkpoint blockade in patients with aRCC with preexisting autoimmune disorders, there have been some studies done in patients with melanoma examining treatment with ipilimumab or anti-PD-1 in this patient population. Here, PDCD1 is linked to Autoimmunity.